| Date Filed | Type | Description |
| 11/17/2017 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 11/14/2017 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 11/07/2017 |
8-K
| Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta... |
| 11/07/2017 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 11/07/2017 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 11/07/2017 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 11/07/2017 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 11/07/2017 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 11/07/2017 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 11/07/2017 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 11/07/2017 |
GN
| Ultragenyx Completes Tender Offer and Acquisition of Dimension Therapeutics |
| 11/06/2017 |
10-Q
| Quarterly Report for the period ended September 30, 2017 |
| 10/31/2017 |
GN
| SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Files Class Action Suit Against Dimension Therapeutics, Inc. |
| 10/26/2017 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 10/26/2017 |
GN
| Ultragenyx and Dimension Announce Expiration of Hart-Scott-Rodino Waiting Period for Ultragenyx's Acquisition of Dimension |
| 10/23/2017 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 10/17/2017 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 10/12/2017 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 10/11/2017 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 10/10/2017 |
SC 14D9
| Form SC 14D9 - Solicitation, recommendation statements: |
| 10/10/2017 |
SC TO-T
| Form SC TO-T - Tender offer statement by Third Party: |
| 10/03/2017 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 10/03/2017 |
SC14D9C
| Form SC14D9C - Written communication relating to third party tender offer: |
| 10/03/2017 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
| 10/03/2017 |
SC14D9C
| Form SC14D9C - Written communication relating to third party tender offer: |
| 10/03/2017 |
8-K
| Quarterly results |
| 10/02/2017 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 10/02/2017 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
| 10/02/2017 |
8-K
| Quarterly results |
| 10/02/2017 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 10/02/2017 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 10/02/2017 |
GN
| Ultragenyx Comments on Dimension Therapeutics' Announcement that Ultragenyx's Offer is a “Superior Proposal” |
| 10/02/2017 |
GN
| REGENXBIO Responds to Notification of a Superior Proposal Under Its Merger Agreement With Dimension Therapeutics |
| 09/25/2017 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
|